| Title: |
Fatal BK polyomavirus-associated pneumonia: report of two cases with literature review. |
| Authors: |
Wang, Yuchen1 (AUTHOR), Fang, Yiling1 (AUTHOR), Yan, Ziyan1 (AUTHOR), Xia, Renfei1 (AUTHOR), Zeng, Wenli1 (AUTHOR), Deng, Wenfeng1 (AUTHOR), Xu, Jian1 (AUTHOR), Feng, Xiaoqin2 (AUTHOR) fxq126126@126.com, Peng, Jie3 (AUTHOR) pjie138@163.com, Miao, Yun1 (AUTHOR) miaoyunecho@126.com |
| Source: |
BMC Infectious Diseases. 9/11/2023, Vol. 23 Issue 1, p1-9. 9p. |
| Subject Terms: |
*HEMATOPOIETIC stem cell transplantation, *GRAFT versus host disease, *STEM cell transplantation, *HEMATOPOIETIC stem cells, *BK virus |
| Abstract: |
Background: In immunocompromised populations, such as patients with AIDS and recipients of solid organ and hematopoietic stem cell transplants, BK polyomavirus (BKPyV) can reactivate and cause several diseases, which can lead to death in their severe forms. Unlike hemorrhagic cystitis and BKPyV-associated nephropathy, BKPyV-associated pneumonia is rare, with only seven known cases worldwide. However, the disease can rapidly progress with extremely high mortality. Case presentation: Herein, we report two cases of BKPyV-associated pneumonia following hematopoietic stem cell transplantation. Both patients had consistent infectious pneumonia and graft-versus-host disease after stem cell transplantation. The diagnosis of BKPyV-associated pneumonia was confirmed by metagenomic next-generation sequencing and polymerase chain reaction after the sudden worsening of the pulmonary infection signs and symptoms concomitant with renal dysfunction and systemic immune weakening. Both patients eventually died of systemic multi-organ failure caused by severe pneumonia. Conclusions: Currently, BKPyV reactivation cannot be effectively prevented. Immunocompromised patients must actively manage their primary lung infections, pay close attention to pulmonary signs and imaging changes. Especially during and after steroid pulse therapy or immunosuppressive therapy for graft versus host diseases, BKPyV load in blood/urine needs to be regularly measured, and the immunosuppressive intensity should be adjusted properly after the BKPyV reactivation diagnosis. Clinical trials of new antiviral drugs and therapies for BKPyV are urgently needed. [ABSTRACT FROM AUTHOR] |
|
Copyright of BMC Infectious Diseases is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
|
Full text is not displayed to guests. |
Login for full access.
|
